Newton Colmore Consulting

03/09/2026

Brain Implant Uses Infrared Light to Send Neural Signals.

ABILITY Neurotech’s optical BCI will soon begin European clinical trial.

Ability Neurotech’s optical BCI will soon begin European clinical trial

03/09/2026

Are you a start‑up or scale‑up in Medical Devices or Biotech looking to add industry experts to your team?

At Newton Colmore, we’ve supported many organisations through their growth journey, and we created Newton4 specifically to help companies scale with confidence.

Newton4 enables you to hire specialist talent while spreading the cost over nine months, giving you added financial protection as you grow.

If you’re planning to expand, get in touch: 0121 268 2240
[email protected]
https://newtoncolmore.com/newton4/

18/08/2026

We are exciting to be working with a deep tech venture in Northern Spain, who is looking for a computational scientist to play a foudational role in how data is extracted, predicted, and utilised in their novel processing technology.

We have a mission to help them hire great people to do great work.

Get in touch if you would like to know more details.

Newton Colmore is proud to be working with a venture that sits at the intersection of AI, biology, and advanced process engineering. We are assisting them in their search for a computational scientist to play a foundational role in the development of their data-rich product.

13/08/2026

Electronics + Sensors + TechBio

I am very excited to be working with a techbio company in Northern Spain, assisting them with their search for three technical problem solvers to join the team.

I am aiming to speak with hands-on electronics engineers, with either hardware design or firmware experience, to develop highly complex sensors that aim to turn an industrial blackbox into a programmable glassbox system.

The hardware design and firmware roles are of vital important to the company as they look to enhance their development capabilities, with real opportunity for growth and domain leadership.

I am also looking for an A* computational scientist to join the team and work on the data science and machine learning aspects of the technology.

If any of these roles have piqued your interest then please do reach out. For the time being, these roles will be full-time onsite in Spain.

13/08/2026

Electronics + Sensors + TechBio

I am very excited to be working with a techbio company in Northern Spain, assisting them with their search for three technical problem solvers to join the team.

I am aiming to speak with hands-on electronics engineers, with either hardware design or firmware experience, to develop highly complex sensors that aim to turn an industrial blackbox into a programmable glassbox system.

The hardware design and firmware roles are of vital important to the company as they look to enhance their development capabilities, with real opportunity for growth and domain leadership.

I am also looking for an A* computational scientist to join the team and work on the data science and machine learning aspects of the technology.

If any of these roles have piqued your interest then please do reach out. For the time being, these roles will be full-time onsite in Spain.

13/08/2026

Hello, everyone. Anyone in my network within the Golden Triangle looking for an associate director/team leader to lead their drug discovery projects?

I am working with a TPD specialist who is looking for their next challenge and I have shared their profile below. They’ve led a 10-person Hit ID team to deliver three degrader projects, and has worked within a CRO setting too.

Ideally looking for a start-up environment which is where they feel they can make a real difference with their scientific nous, adaptability, and experience.

Happy to setup an intro if the profile sounds like it could be of interest.

Explore a selection of highly skilled candidates ready to join your team across Medical Devices, Biotech, Drug Discovery, DeepTech and other complex fields. View profiles of engineers, scientists, and leaders available now through Newton Colmore Consulting.

10/08/2026

Here is Matt Lowdon's deal summary cover news across our core sectors; Medical Devices and Biotechnology. Headlines include news from medical robotics, molecular glues, cardiovacular therapeutics and more. Congratulations to all involved and have a good week.

🔔 Tarsus Pharmaceuticals, Inc. Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals, Inc. Pharmaceuticals for its phase 3 retinal disease therapy, touted as a potential blockbuster.

🔔 Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.

🔔 Australian medical robotics company Vexev has raised $6 million to advance FDA clearance and US commercialisation of VxWave, its AI-powered robotic ultrasound platform for vascular imaging

🔔 Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio

🔔 Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.

🔔 Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer Holdings Corporation private for approximately $5.7 billion.

🔔 Scottish biotech Mironid® Limited has raised €40 million in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease through clinical development.

🔔 AstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.

🔔 iRhythm Technologies, Inc. Technologies plans to acquire VitalConnect for $237.5m in cash and about $50m in iRhythm common stock.

Hi, everyone. A good amount of deal news to summarise for you this week. Headlines include news from medical robotics, molecular glues, cardiovacular therapeutics and more. Congratulations to all involved and have a good week. 🔔 Tarsus Pharmaceuticals is fronting $450 million…

06/08/2026

Sleep Patch Could Track Brain’s Nightly Cleansing Ritual.

Monitoring the elusive activity of the glymphatic system could aid Alzheimer’s research.

Monitoring the elusive activity of the glymphatic system could aid Alzheimer’s research

04/08/2026

Perhaps a bit of a summer slowdown this week regarding deal news. Here are the top headlines I found, with news from sleep apnea, ablation technology, AI drug discovery and more. Let me know if I missed anything.

🔔 Medtronic leads $37M investment in ablation mapping startup CoreMap

🔔Xeltis has raised an additional €20.5m to expand its vascular implant programmes in Europe and the US.

🔔Cambridge-based health tech company Qureight has secured £15m in Series B funding to expand its AI-powered clinical trial imaging platform.

🔔UK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million.

🔔Berlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline.

🔔Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch

🔔GSK is boosting its AI chops with a new deal worth up to $110 million with Relation.

🔔The private equity arm of Goldman Sachs has agreed to acquire control of ​Italian medical equipment maker Numantec from White ‌Bridge Investment

===============

Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.

Medtronic leads $37M investment in ablation mapping startup CoreMap   Xeltis has raised an additional €20.5m to expand its vascular implant programmes in Europe and the US.   Cambridge-based health tech company Qureight has secured £15m in Series B funding to expand…

29/07/2026

Researchers at UCL have developed an AI model to identify patients with locally advanced re**al cancer who may benefit from an intensified treatment previously thought to offer limited clinical advantage.